Neogen Co. (NEOG) Receives $63.25 Average Target Price from Analysts

Neogen Co. (NASDAQ:NEOG) has earned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $63.25.

A number of research firms have issued reports on NEOG. BidaskClub cut Neogen from a “buy” rating to a “hold” rating in a report on Thursday. Stephens reiterated a “hold” rating and set a $62.00 target price on shares of Neogen in a report on Wednesday. Roth Capital set a $62.00 target price on Neogen and gave the stock a “hold” rating in a report on Thursday, January 4th. Zacks Investment Research upgraded Neogen from a “hold” rating to a “strong-buy” rating and set a $69.00 target price for the company in a report on Saturday, January 6th. Finally, Craig Hallum increased their target price on Neogen from $46.50 to $60.00 and gave the stock a “hold” rating in a report on Thursday, December 7th.

In other news, VP Edward Bradley sold 17,824 shares of the stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $80.32, for a total transaction of $1,431,623.68. Following the completion of the transaction, the vice president now directly owns 27,212 shares in the company, valued at approximately $2,185,667.84. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider James L. Herbert sold 26,000 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $81.45, for a total transaction of $2,117,700.00. Following the transaction, the insider now owns 879,430 shares of the company’s stock, valued at $71,629,573.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,824 shares of company stock valued at $3,870,364. Company insiders own 4.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of NEOG. Conestoga Capital Advisors LLC boosted its stake in shares of Neogen by 20.2% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 958,784 shares of the company’s stock worth $74,267,000 after buying an additional 161,170 shares during the last quarter. Wasatch Advisors Inc. acquired a new stake in Neogen in the 3rd quarter valued at about $11,016,000. Citadel Advisors LLC lifted its stake in Neogen by 338.6% in the 3rd quarter. Citadel Advisors LLC now owns 143,553 shares of the company’s stock valued at $11,120,000 after purchasing an additional 110,821 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Neogen by 32.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 372,276 shares of the company’s stock valued at $25,728,000 after purchasing an additional 91,390 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Neogen by 71.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 194,552 shares of the company’s stock valued at $13,445,000 after purchasing an additional 80,775 shares during the last quarter. Institutional investors own 86.96% of the company’s stock.

Neogen (NASDAQ:NEOG) traded down $0.08 during mid-day trading on Wednesday, reaching $59.12. The company’s stock had a trading volume of 155,989 shares, compared to its average volume of 172,271. The company has a market cap of $3,050.14, a PE ratio of 58.82, a PEG ratio of 3.73 and a beta of 1.54. Neogen has a 52-week low of $44.63 and a 52-week high of $64.42.

Neogen (NASDAQ:NEOG) last released its earnings results on Wednesday, January 3rd. The company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.07. The firm had revenue of $101.80 million during the quarter, compared to analysts’ expectations of $102.46 million. Neogen had a return on equity of 10.72% and a net margin of 13.47%. The company’s revenue was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.29 EPS. research analysts anticipate that Neogen will post 1.06 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.thestockobserver.com/2018/01/13/neogen-co-neog-receives-63-25-average-target-price-from-analysts.html.

Neogen Company Profile

Neogen Corporation develops, manufactures and markets a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation.

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply